Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant360 is a molecular diagnostic test that measures 73 cancer-related genes from circulating tumor deoxyribonucleic acid (ctDNA). Its Guardant360 process includes blood collection, laboratory processing, analysis and reporting. Guardant360 is used for a range of applications, including translational science research and identifying target patient populations, drug development and commercialization post-drug approval.
Q3 2019(9/30/19): Cash 523M. Loss：12.79M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
|Date||Sales||% last year||% last quarter|
Total institutions: 274，no change
Shares hold: 73942.6k shares. no change
shares% hold: 78.74%，no change